Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Advances of Membrane Vesicles in Drug Delivery Systems"
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: closed (20 February 2023) | Viewed by 21472
Special Issue Editor
2. College of Life Sciences, Nanchang University, Nanchang 330031, China
Interests: lipoproteins, gangliosides, and atherosclerosis; drug delivery systems; membrane vesicles; pharmacology of cyclodextrins; fluorescent probes/sensors
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Drug delivery systems (DDSs) are defined as formulations or devices that deliver therapeutic substances specifically to their sites of action without reaching nontarget sites (cells, tissues, or even organs). Many benefits to drugs can be achieved by drug delivery systems, including an elevated stability, higher water solubility, prolonged circulation time, better sustained drug release, stronger tissue/cell targetability, lower drug dosage, impaired side effects, enhanced efficacy, etc. Over the last two decades, bioinspired (or biologically inspired) drug delivery systems have been intensively studied. Compared with traditional DDSs, the advantages of bioinspired DDSs include lower/no immunogenicity, biocompatibility, biodegradability, better safety, among others. By mimicking natural components inside the body, many bioinspired DDSs have been tested, including biomolecule (e.g., peptides)-, lipid-protein complex (e.g., reconstituted high-density lipoprotein)-, membrane vesicle-, virus-, and even whole cell (e.g., bacterium, erythrocyte, platelet, stem cell)-inspired DDSs. For example, membrane vesicles for drug delivery systems can be derived from different types or parts of cells, including well-known extracellular vesicles (EVs; e.g., exosomes, microvesicles or microparticles, and apoptotic bodies) released from cells, outer membrane vesicles (OMVs) from bacteria, cell-bound membrane vesicles (CBMVs) isolated in situ from cell surfaces, membrane vesicles reorganized after the isolation of the plasma membrane of cells, etc. The bearing of some specific molecules, which originally exists on/in the source cells enables membrane vesicles to have specific functions (e.g., making the target cells have some properties of the source cells). In recent years, membrane vesicle-inspired DDSs have been rapidly developed. These latest advances should be concisely summarized/reviewed, and original studies reported as soon as possible. This Special Issue of Pharmaceutics aims to collect the papers that explore the advances in membrane vesicle-based drug delivery systems.
The considered papers include, but are not limited to, the following aspects:
- Development of methods/techniques for the isolation/preparation or characterization of membrane vesicles as drug delivery systems.
- Evaluation of the biochemical or biophysical properties of membrane vesicles.
- Modification of membrane vesicles for better performance.
- Pharmacokinetics and pharmacodynamics of membrane vesicles as drug delivery systems.
- Related mechanisms of membrane vesicle-based drug delivery systems.
- Diagnostic, therapeutic or clinical applications of membrane vesicle-based drug delivery systems for different diseases.
Prof. Dr. Yong Chen
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.